phase readout
saveNCT05846737: BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
WITHDRAWNupdated 4d ago
community read0 votes
Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: PHASE2. Conditions: Multiple Myeloma
view source ↗
comments(0)
5-min edit window · permanent after that